Will Labor Requirements Increase in Meeting DSCSA Milestones?

With many companies either facing or concerned about labor shortages in manufacturing, an expert from Cardinal Health notes that outbound scanning alone may require a 12 to 15% increase in headcount in their operations.

For product traceability, outbound scanning alone is expected to increase labor by a minimum of 12 to 15% based on recent time studies, per Cardinal Health.
For product traceability, outbound scanning alone is expected to increase labor by a minimum of 12 to 15% based on recent time studies, per Cardinal Health.

Data exchange between trading partners is a key component of meeting Drug Supply Chain Security (DSCSA) requirements for unit-level traceability of prescription drugs. With only two years left to meet 2023 milestones, industry groups and experts are urging manufacturers to begin onboarding with distributors for data exchange as soon as possible.


Read article   For intro material on sharing EPCIS events and onboarding, read: Pharma Supply Chain: Master Data Exchange in 2021.


While much of the focus has been on the technological challenges around receiving EPCIS files, Maryann Nelson, regulatory manager at Cardinal Health, Inc., discussed a new need developing in the space at HDA’s Traceability Online Seminar: labor.

First, the technological challenges are quite serious with limited time left. In November 2023, wholesale distributors like Cardinal Health must receive that EPCIS serialized transaction information (TI) and transaction statement (TS) from manufacturers prior to accepting ownership of the product, replacing the TI, TS, and transaction history (TH) shared today via advanced shipping notice (ASN).

Nelson said Cardinal Health expects to onboard approximately 500 suppliers with point-to-point direct connections. “Cardinal Health has been ready to receive EPCIS serialized data for well over a year now. And we've really tried to communicate to manufacturers not to wait. Don't use the enforcement discretion granted by FDA as a reason to pause efforts, if you will,” she explained. “We do remain concerned, however, about EPCIS adoption. Currently only 42 manufacturers are sending us serialized data in production, so that's less than 10%.”

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
List: Digitalization Companies From PACK EXPO